Global Pulmonary Arterial Hypertension (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) Market 2015-2020

Jul 21, 2015, 08:13 ET from Research and Markets


DUBLIN, July 14, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/z8pwgj/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering.

The global PAH market has been segmented into prostacyclin and prostacyclin analogs, ERAs, PDE-5 inhibitors, and sGC stimulators, based on the commercially-available drug classes, to treat PAH. Of these, ERAs represented the largest segment in 2013 with a revenue share of 55.8%.

However, during the forecast period, the prostacyclin and prostacyclin analogs segment is expected to record the highest growth, mainly due to the approval of Orenitram (treprostinil extended release tablet) in December 2013 and the anticipated approval of Uptravi (selexipag) in the first quarter of 2016. Adempas (riociguat) is the only approved sGC stimulator for the treatment of PAH. Adempas was first approved by the U.S. FDA in October 2013.

In terms of geography, the global pulmonary arterial hypertension (PAH) market has been segmented into four major regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America, with a share of 44.6%, represented the largest regional market for PAH in terms of revenue in 2013, followed by Europe. These two developed regions are expected to witness substantial growth during the forecast period, primarily due to the recently approved PAH drugs in the market and products that are anticipated to receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New Zealand exhibit immense opportunities for the companies operating in the PAH market.

In RoW, the low level of awareness regarding the diagnosis and treatment of PAH is one of the prime reasons restraining the market growth. However, during the forecast period, growing awareness regarding PAH would drive growth of the market.

Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation are the key players operating in the global PAH market.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Global Pulmonary Arterial Hypertension (PAH) Market Overview

Chapter 4 Global Pulmonary Arterial Hypertension (PAH) Market Revenue, by Drug Class

Chapter 5 Pipeline Analysis: Global Pulmonary Arterial Hypertension (PAH) Market

Chapter 6 Global Pulmonary Arterial Hypertension (PAH) Market, By Geography

Chapter 7 Recommendations

Chapter 8 Company Profiles

- Actelion Pharmaceuticals, Ltd. - Bayer HealthCare - Gilead Sciences, Inc. - GlaxoSmithKline plc - Novartis International AG - Pfizer, Inc. - United Therapeutics Corporation

For more information visit http://www.researchandmarkets.com/research/z8pwgj/pulmonary

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 



SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com